Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single‑center retrospective study
Treatment strategies included supportive care, interferon, hydroxyurea, and ruxolitinib.
The study investigated clinical, molecular, and treatment patterns in 56 patients with myelofibrosis (PMF n=33, SMF n=23) and identified distinct phenotypic differences and a heterogeneous mutational landscape with JAK2, CALR and MPL as the top driver mutations.
These insights delineate‐topical therapeutic options and illustrate the molecular underpinnings of myelofibrosis, aiding clinicians to tailor treatment and prognostication.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
- Population Pharmacokinetics and Exposure‑Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
- SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN
- Current treatments, practical management, and emerging investigational therapies for myelofibrosis